PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY

Brief description of study

The purpose of the study is to evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M +Len) compared with rituximab in combination with lenalidomide (R+Len) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) who were treated with at least 1 prior systemic therapy. We want to compare M+Len to R+Len for overall survival rates, progression-free survival rates, compete response rates, and objective response rates. In the study, we want to identify biomarkers that are predictive of response to M+Len and can provide evidence of M + Len activity, or can increase the knowledge and understanding of disease biology.


Clinical Study Identifier: s21-00033
ClinicalTrials.gov Identifier: NCT04712097
Principal Investigator: Catherine M Diefenbach.
Other Investigators: Kenneth B Hymes, Marc Justin Braunstein, Maxim Kreditor, Bruce G Raphael, Michael L. Grossbard, Ellaine R Yap, Shella Saint Fleur-Lominy, David Kaminetzky, Tibor Moskovits, Bonnie Kiner-Strachan, Thaleshravi Prashad.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.